肝毒性后成功耐受伏立康唑再激发。
Rechallenge of voriconazole successfully tolerated after hepatic toxicity.
作者信息
Narumoto O, Suzuki J, Takeda K, Tamura A, Nagai H, Matsui H
机构信息
Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
出版信息
Respir Med Case Rep. 2020 Aug 13;31:101191. doi: 10.1016/j.rmcr.2020.101191. eCollection 2020.
Infections caused by Aspergillus species are often life-threatening. Drugs effective for Aspergillus infection are limited. Voriconazole is one of the most important drugs, however, considerable portion of patients experience liver toxicity and have to stop the drug administration. We frequently experience liver toxicity even though the serum concentration of voriconazole is within the target range. Historically, in some life-threatening situations like tuberculosis, where a suitable alternative is unavailable, rechallenge has been attempted. However, there have been no report on the rechallenge of voriconazole. We report cases of successful re-administration of voriconazole after liver toxicity.
曲霉菌属引起的感染往往危及生命。对曲霉菌感染有效的药物有限。伏立康唑是最重要的药物之一，然而，相当一部分患者会出现肝毒性，不得不停止用药。即使伏立康唑的血清浓度在目标范围内，我们仍经常遇到肝毒性情况。从历史上看，在一些危及生命的情况下，如结核病，在没有合适替代药物时，曾尝试再次用药。然而，尚无关于伏立康唑再次用药的报道。我们报告了肝毒性后成功再次使用伏立康唑的病例。
Zotero 插件